{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-malignant+Diseases&page=8", "query": { "condition": "Non-malignant Diseases", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 768, "total_pages": 77, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-malignant+Diseases&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-malignant+Diseases&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T11:48:55.740Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Anaplastic Thyroid Cancer", "Bone Metastases", "Carcinoma of the Appendix", "Distal Urethral Cancer", "Fallopian Tube Cancer", "Gastrinoma", "Glucagonoma", "Inflammatory Breast Cancer", "Insulinoma", "Liver Metastases", "Localized Unresectable Adult Primary Liver Cancer", "Lung Metastases", "Male Breast Cancer", "Malignant Pericardial Effusion", "Malignant Pleural Effusion", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Parathyroid Cancer", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Newly Diagnosed Carcinoma of Unknown Primary", "Occult Non-small Cell Lung Cancer", "Pancreatic Polypeptide Tumor", "Primary Peritoneal Cavity Cancer", "Proximal Urethral Cancer", "Pulmonary Carcinoid Tumor", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adrenocortical Carcinoma", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Carcinoma of Unknown Primary", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Pancreatic Cancer", "Recurrent Parathyroid Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Thyroid Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Recurrent Vaginal Cancer", "Recurrent Vulvar Cancer", "Skin Metastases", "Small Intestine Adenocarcinoma", "Somatostatinoma", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Adrenocortical Carcinoma", "Stage III Bladder Cancer", "Stage III Cervical Cancer", "Stage III Colon Cancer", "Stage III Endometrial Carcinoma", "Stage III Esophageal Cancer", "Stage III Follicular Thyroid Cancer", "Stage III Gastric Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Pancreatic Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Prostate Cancer", "Stage III Rectal Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Anal Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Anal Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Adrenocortical Carcinoma", "Stage IV Anal Cancer", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Gastric Cancer", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Pancreatic Cancer", "Stage IV Papillary Thyroid Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Thyroid Gland Medullary Carcinoma", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Urethral Cancer Associated With Invasive Bladder Cancer", "WDHA Syndrome" ], "interventions": [ { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" }, { "name": "ABI-007/carboplatin/trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-10-11T11:48:55.740Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004074" }, { "nct_id": "NCT01169584", "title": "Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Rhabdomyosarcoma", "Lymphoma", "Wilm's Tumor", "Ewing's Sarcoma" ], "interventions": [ { "name": "Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jennerex Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 6, "start_date": "2010-08", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2016-01-21", "last_synced_at": "2026-10-11T11:48:55.740Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Houston, Texas", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01169584" }, { "nct_id": "NCT03513328", "title": "Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bone Marrow Failure Syndrome", "Thalassemia", "Sickle Cell Disease", "Diamond Blackfan Anemia", "Acquired Neutropenia in Newborn", "Acquired Anemia Hemolytic", "Acquired Thrombocytopenia", "Hemophagocytic Lymphohistiocytoses", "Wiskott-Aldrich Syndrome", "Chronic Granulomatous Disease", "Common Variable Immunodeficiency", "X-linked Lymphoproliferative Disease", "Severe Combined Immunodeficiency", "Hurler Syndrome", "Mannosidosis", "Adrenoleukodystrophy" ], "interventions": [ { "name": "Thiotepa--single daily dose", "type": "DRUG" }, { "name": "Thiotepa--escalated dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Months to 39 Years" }, "enrollment_count": 6, "start_date": "2018-06-15", "completion_date": "2023-02-19", "has_results": true, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-10-11T11:48:55.740Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03513328" }, { "nct_id": "NCT00002663", "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "EBV-induced Lymphomas", "EBV-associated Malignancies", "Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma" ], "interventions": [ { "name": "Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Atara Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 58, "start_date": "1995-03", "completion_date": "2019-07", "has_results": true, "last_update_posted_date": "2023-02-13", "last_synced_at": "2026-10-11T11:48:55.740Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002663" }, { "nct_id": "NCT00508144", "title": "Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Alimta", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2005-09", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-02-13", "last_synced_at": "2026-10-11T11:48:55.740Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00508144" }, { "nct_id": "NCT01088763", "title": "Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood Infratentorial Ependymoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Gonadotroph Adenoma", "Pituitary Basophilic Adenoma", "Pituitary Chromophobe Adenoma", "Pituitary Eosinophilic Adenoma", "Prolactin Secreting Adenoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Spinal Cord Neoplasm", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Pituitary Tumor", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "T-cell Childhood Acute Lymphoblastic Leukemia", "T-cell Large Granular Lymphocyte Leukemia", "TSH Secreting Adenoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 129, "start_date": "2010-03", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2014-11-05", "last_synced_at": "2026-10-11T11:48:55.740Z", "location_count": 11, "location_summary": "Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088763" }, { "nct_id": "NCT04503265", "title": "A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Neoplasm", "Breast Cancer", "Ovarian Cancer", "Homologous Recombination Deficiency", "Prostate Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "AMXI-5001:Dose Escalation Phase I", "type": "DRUG" }, { "name": "AMXI-5001:Dose Expansion Phase II", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AtlasMedx, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2020-08-12", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-05-01", "last_synced_at": "2026-10-11T11:48:55.740Z", "location_count": 4, "location_summary": "Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04503265" }, { "nct_id": "NCT00004230", "title": "Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "captopril", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "1999-10", "completion_date": "2002-03", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-10-11T11:48:55.740Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004230" }, { "nct_id": "NCT00744692", "title": "Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Malignant Disorders", "Immunodeficiencies", "Congenital Marrow Failures", "Hemoglobinopathies", "Inborn Errors of Metabolism", "Sickle Cell", "Thalassemia", "Lysosomal Storage Disease" ], "interventions": [ { "name": "Unrelated Umbilical Cord Blood Transplant", "type": "BIOLOGICAL" }, { "name": "Reduced Intensity Conditioning", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 22, "start_date": "2008-10", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2014-08-13", "last_synced_at": "2026-10-11T11:48:55.740Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00744692" }, { "nct_id": "NCT00529087", "title": "Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Constipation" ], "interventions": [ { "name": "N-methylnaltrexone bromide (MOA-728)", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2007-08", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-10-11T11:48:55.740Z", "location_count": 78, "location_summary": "Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00529087" } ] }